Opus Genetics (IRD) Net Equity Issued and Repurchased (2011 - 2026)

Opus Genetics (IRD) has reported Net Equity Issued and Repurchased for 13 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased rose 450.12% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $4.5 million (down 25.86% YoY), while the FY2025 annual figure was $5.8 million, up 29.09% from the prior year.
• Net Equity Issued and Repurchased rose to $2.2 million in Q1 2026 per IRD's latest filing, from $179000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $5.2 million in Q3 2024 and bottomed at $28000.0 in Q4 2022.
• Historically, Net Equity Issued and Repurchased has averaged $1.9 million across 5 years, with a median of $1.5 million in 2022.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased sank 99.88% — and 2023, when it soared 13275.0%.
• Opus Genetics' Net Equity Issued and Repurchased stood at $28000.0 in 2022, then jumped by 13275.0% to $3.7 million in 2023, then surged by 38.85% to $5.2 million in 2024, then sank by 96.56% to $179000.0 in 2025, then soared by 1156.98% to $2.2 million in 2026.
• Business Quant data shows IRD's Net Equity Issued and Repurchased at $2.2 million in Q1 2026, $179000.0 in Q4 2025, and $1.7 million in Q3 2025.